You're viewing the US edition You can switch to the UK, AU or IE homepage at any time using this menu. FBI officials are charged over Hunter Biden laptop as dramatic'cover-up' saga sparks fury about politicization on eve of midterms Trump's House nightmare deepens as famed election guru pushes 19 more races towards Democrats Damning video reveals vulgar rant of MAGA star Joe Mitchell, then-19, about'black women' and not liking'f***ing white people' while boasting about his own manhood AMANDA PLATELL: Is this the moment we should all feel sorry for Meghan? I have been among her harshest critics... but she may have been harbouring a deeply disturbing secret all along JD Vance's confession aboard Air Force Two completely changed how I see this election. Even my Democrat sources are privately admitting they agree - there's been a monumental shift in the midterms: MARK HALPERIN Met Police did not launch child sex probe into Thomas Markle - as force hunts for'disturbing' 2018 letter Meghan revealed after it emerged her father faces abuse photos investigation Dead-eyed and exhausted, Prince Harry should just come out and admit it he must know it's all over: MAUREEN CALLAHAN REBECCA ENGLISH: Going on Graham Norton is risky business for a royal... Real reason Matthew Perry kept taking ketamine: Family reveal powerful force behind voracious eight-injections-a-day habit... as they slam his jailed assistant for'duping' them Steffi Graf's secret heartache: Inside star's brutal childhood on tennis circuit and disturbing claims about her father... as her brother's videos from the Las Vegas tunnels threaten to turn her'dream' new life into a nightmare DR PHILIPPA KAYE: After the weather changed, I suddenly saw so many patients with a frozen shoulder. Epic downfall of Emmy-winning TV reporter as she's accused of fueling America's opioid crisis in $14million scheme NYC woman sobs as she accuses Douglas Elliman realtor of accidentally texting her to say'Ugh, they are black' as she arrived to view rental Police handling of Kurt Cobain death evidence faces official investigation amid claim ex-chief admitted key details in case didn't add up US drinking water may contain twice as many'forever chemicals' as reported... see the levels in your state MORE: I'm a Christian leader who attended a secret meeting with Anthropic.

Vik Chandra, CEO of uMETHOD, talked with Fox News Digital about how his company's AI tool, RestoreU, is helping physicians pinpoint better treatment plans for their dementia patients. More than six million Americans are living with Alzheimer's disease -- and one in three seniors dies with the disease, according to statistics from the Alzheimer's Association. With so many different factors -- genetics, lifestyle and environment -- influencing a person's risk of developing Alzheimer's, many doctors are moving away from one-size-fits-all approaches and calling for more individualized treatments. It's a concept known as precision medicine. And it's what inspired a company called uMETHOD to create RestoreU, a tool that uses artificial intelligence to help physicians create personalized care plans for patients with Alzheimer's and other types of dementia.

Every week, Q.ai releases a thematic screen, courtesy of the Forbes AI Investor platform. With real-time insights and our proprietary internal ratings system – not to mention our artificial intelligence unit – we provide the data you need to build your portfolio in the long-term. This week, our thematic focus is on Quality Value. Q.ai runs factor models daily to get the most up-to-date reading on stocks and ETFs. Our deep-learning algorithms use Artificial Intelligence (AI) technology to provide an in-depth, intelligence-based look at a company – so you don't have to do the digging yourself.

Quest Diagnostics, a provider of diagnostic information services, and hc1, the bioinformatics leader in precision testing has unveiled Quest Lab Stewardship powered by hc1, an innovative new service that employs machine learning to harmonize laboratory testing across health systems in order to help optimize laboratory test utilization. Healthcare system wastes around $765 billion a year, due to factors such as unnecessary or inefficiently delivered services as well as missed prevention opportunities, according to the National Academy of Medicine. Although laboratory testing reflects only about 2-3% of overall health care costs in the United States, ordering lab tests is healthcare's single highest-volume activity.[ii] Under-and overutilization* of lab tests can adversely affect clinical decisions, such as by prompting unnecessary or delayed procedures to address missed diagnoses. Quest Lab Stewardship is the result of a strategic collaboration between Quest and hc1 focused on improving costs and clinical impact of lab testing, in- and out- of hospital settings.

Last year, I posted about Alexa being able used to access complex health information. Microsoft, on the other hand, has taken a different approach to the use of a chatbot/AI for healthcare. Instead of the chatbot being able to access your health record, why not have it answer routine questions patients have prior to an appointment? With this goal in mind, Microsoft has created the Microsoft Healthcare Bot, which is a service that allows healthcare organizations to streamline their processes, and take some of the workload off of their staff. What I like about this service is that it allows for "basic" questions to be answered – issues like clinic hours, when results can be expected, or whether to fast before a blood test, can all be answered. It also has a built-in escalation system, where if a patient needs more information, or if they can't get the answer they need, the AI will pass them on to a person who can answer their questions with the current transcript, ensuring a smooth patient experience.

CAMBRIDGE, MA - 10 Nov 2016: IBM Watson Health (NYSE: IBM) and the Broad Institute of MIT and Harvard today announced a research initiative aimed at discovering the basis of cancer drug resistance. The five year, $50 million project will study thousands of drug resistant tumors and draw on Watson's computational and machine learning methods to help researchers understand how cancers become resistant to therapies. The anonymized data will be made available to the scientific community to catalyze research worldwide. IBM Watson Health and the Broad Institute bring the data prowess of Watson to study cancer drug resistance in a $50M research collaboration. The goal is to identify patterns that could reveal clues into one of the greatest medical mysteries of cancer.

CAMBRIDGE, MA - 10 Nov 2016: IBM Watson Health (NYSE: IBM) and the Broad Institute of MIT and Harvard today announced a research initiative aimed at discovering the basis of cancer drug resistance. The five year, $50 million project will study thousands of drug resistant tumors and draw on Watson's computational and machine learning methods to help researchers understand how cancers become resistant to therapies. The anonymized data will be made available to the scientific community to catalyze research worldwide. To help understand how cancers become resistant to specific therapies, Broad Institute will generate tumor genome sequence data from patients who initially respond to treatment but who then become drug-resistant. Broad will use new genome-editing methods to conduct large-scale cancer drug resistance studies in the laboratory, to help identify tumors' specific vulnerabilities.

Cancer treatments are about to get an injection of cognitive computing. On Tuesday, IBM Watson Health and Quest Diagnostics launched IBM Watson for Genomics--a service that combines Watson's AI capabilities with genomic tumor sequencing to determine the best course of treatment for individual patients. This is the first time Watson for Genomics will be widely available to patients and physicians nationwide, according to a press release, as Quest Diagnostics serves half of US physicians and hospitals. Quest estimates that it will provide this service for thousands of oncologists who provide about 70% of cancer care in the nation. Tumor mutations vary for each individual, and treatment success often depends on how well a physician can match a therapy to a mutation.

IBM announced Monday that it's partnering with Quest Diagnostics to advance precision medicine in the treatment of cancer across the US. With the launch of a new service called IBM Watson Genomics from Quest Diagnostics, the two companies are combining Watson's cognitive computing power with Quest's expertise in tumor analysis. The service is also supported by the Memorial Sloan Kettering Cancer Center (MSK), which will give Watson access to OncoKB, its database of clinical evidence. The Broad Institute of MIT and Harvard are also providing additional genome sequencing capabilities. The new service uses laboratory sequencing and analysis of a tumor's genomic makeup to identify mutations that can be associated with targeted therapies and clinical trials.